← Who reports today · Health Care
ZTS · Q2 2026
Archived report (Q2 2026). Latest deep dive →
Net income attributable to Zoetis Inc.
$691M
down 4.8% y/y
Revenue
$2,468M
down 0.2% y/y
Operating income (calculated)
$922M
down 4.7% y/y
The quarter in brief
Revenue fell 0.2% y/y to $2.47B, operating margin 37.4% vs 39.1%, net income $691M (−4.8% y/y).
All figures in $M.
| Line item | Amount and change |
|---|---|
| Revenue | $2,468 · −0.2% |
| Cost of sales | $673 · +1.4% |
| Selling, general and administrative expenses | $592 · −3.6% |
| Research and development expenses | $173 · +4.2% |
| Amortization of intangible assets | $31 · −6.1% |
| Restructuring charges and certain acquisition and divestiture-related costs | $77 · +157% |
| Operating income (calculated) | $922 · −4.7% · 37.4% margin |
| Interest expense, net of capitalized interest | $61 · +15.1% |
| Other (income)/deductions–net | $5 · vs −$2 |
| Income before provision for taxes on income | $866 · −5.0% |
| Provision for taxes on income | $175 · −5.9% · 20.2% effective rate |
| Net income attributable to Zoetis Inc. | $691 · −4.8% · $1.65/sh · 28.0% margin |
Verdict: revenue fell 0.2% y/y to $2.47B, operating margin 37.4% vs 39.1%, net income $691M (−4.8% y/y).
Guidance for adjusted diluted EPS was revised to $6.15 - $6.25.
Source and notation
Source: Zoetis press release, 8-K EX-99.1 of 08/06/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL. Operating income is calculated (revenue less costs and operating expenses): the release does not report it.
Open as an image: ZTS, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “ZTS Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/zts/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/zts/q2-2026"><img src="https://whoreportstoday.com/t/zts/q2-2026/sankey.png" alt="ZTS Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/zts/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/zts/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/zts/q2-2026">ZTS Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Adjusted net income was $781 million, or $1.87 per diluted share.
- Operating income was $922M, a 37.4% margin vs 39.1% a year earlier.
- The effective tax rate was 20.2% vs 20.4% a year earlier.
- Diluted EPS was $1.65 vs $1.63 a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
ZTS — an animal health company that discovers, makes and sells medicines, vaccines, diagnostics and genetic tests for pets, horses and livestock, selling mainly to veterinarians and livestock producers in more than 100 countries.
It manages the business through two geographic segments, the United States and International, each covering both companion animal and livestock products. · Source: annual report (Form 10-K, SEC)
More reports: A · Q3 FY2026 · ABBV · Q3 2026 · ABT · Q3 2026 · ALGN · Q3 2026 · AMGN · Q3 2026 · BAX · Q3 2026 · BDX · Q4 FY2026 · BIIB · Q3 2026 · BMY · Q3 2026 · BSX · Q3 2026 · all reports